Insulin Patch Pump Occlusion Detection — PatSnap Eureka
Insulin Patch Pump Occlusion Detection Pressure Sensors
Occlusion detection is a patient-safety-critical function in insulin patch pumps—any blockage risks dangerous under-dosing in diabetic patients. This report maps pressure sensor–based detection across four sensing clusters from 1989 to 2026.
Pressure-Based Occlusion Detection: A 37-Year Innovation Arc
Occlusion detection in insulin infusion and patch pump systems centers on real-time monitoring of fluid pressure signatures within the drug delivery path. Blockages upstream (reservoir side) or downstream (cannula/patient side) generate characteristic pressure anomalies that onboard algorithms can sense, profile, and classify. Within this dataset, four principal sensing modalities are represented: direct fluid pressure transduction, membrane-and-optical systems, motor/drive-train parameter monitoring, and infrared reflective tube-wall deformation sensors.
The earliest filings in this dataset address IV-line infusion pumps broadly, while later filings progressively miniaturize and specialize these mechanisms for wearable and patch-form-factor insulin delivery devices. The foundational 1989 patent by Pacesetter Infusion / MiniMed Technologies established the core architecture: a piezoresistive downstream pressure transducer coupled to control logic, alarm circuitry, and baseline pressure averaging.
The mid-stage development period (2005–2015) saw Tandem Diabetes Care build a pressure-differential patent family tuned to basal and bolus insulin delivery modes, while Insulet Corporation developed optical membrane-deflection systems for OmniPod-type patch pumps. ZEVEX, Inc. prosecuted a highly geographically distributed family across US, CA, AU, EP, WO, and IN jurisdictions between 2013 and 2017.
Among the most recent filings (2023–2026) in this dataset, Insulet Corporation re-entered with advanced pressure-profile analysis for fluid path classification, and Becton Dickinson filed motor current–based sensing methods to eliminate dedicated pressure sensors. In retrieved records, Nestec S.A. leads by filing volume with approximately 11 records, followed by ZEVEX / Moog Inc. with approximately 10 records in this dataset.
Sensing Cluster Distribution and Filing Activity Over Time
The retrieved records span four technology clusters and a 37-year filing timeline. Direct fluid pressure transduction is the most represented cluster in this dataset, while pressure-profile algorithmic classification represents the fastest-growing recent direction.
Patent Records by Sensing Modality Cluster (Dataset Snapshot)
In this dataset, direct fluid pressure transduction (strain gauge / piezoresistive) accounts for the largest share of retrieved records, followed by membrane-deflection/optical and drive-train/motor parameter approaches.
↗ Click bars to exploreFiling Activity by Era — Occlusion Detection Patents (Dataset Snapshot)
In this dataset, filing activity across retrieved records shows a foundational cluster (1989–2003), a mid-stage development burst (2005–2015), and renewed recent activity (2021–2026) driven by algorithmic and sensor-minimization approaches.
↗ Click bars to exploreWhere Occlusion Detection Pressure Sensors Are Deployed
Pressure-based occlusion detection spans ambulatory insulin delivery, hospital IV infusion, broader ambulatory drug delivery, and dialysis therapy. The retrieved records reflect a field that originated in clinical IV settings and has progressively migrated toward wearable, miniaturized patch pump systems.
Ambulatory Insulin Patch Pumps
Tandem Diabetes Care (t:slim X2), Insulet Corporation (OmniPod), MiniMed/Medtronic, and Bigfoot Biomedical are the primary assignees serving this segment in retrieved records. A 2021 literature study benchmarked occlusion detection time for Accu-Chek Solo, A6 TouchCare, and OmniPod at basal rates of 0.1 and 1 U/h, confirming detection latency as a critical performance metric. A 2025 Indian filing introduces a fully integrated wearable patch pump combining MEMS pressure and flow sensors with BLE connectivity, haptic alerts, and NFC-based activation.
Wearable Insulin DeliveryHospital IV Infusion Therapy
Hospira/Abbott Laboratories, ICU Medical, Baxter International, Carefusion 303, and DEKA Products developed pressure-based occlusion systems for clinical IV infusion settings where cassette-based pumps deliver broad drug portfolios. The Hospira/Abbott/ICU Medical strain-gauge cassette architecture appears across US, EP, AU, CA, and WO jurisdictions. DEKA’s multi-phase pressure algorithm applies an occlusion metric (OM = P − P_avg) across prime, start-up, and steady-state phases with independent threshold tests (EP filing, 2016).
Clinical IV InfusionAmbulatory Non-Insulin Drug Delivery
Baxter International’s ambulatory pump portfolio addresses broader drug delivery including pain management and chemotherapy pumps, using time-series pressure difference value comparison (2003, US). The approach monitors sequential pressure delta values over pump cycles to flag occlusion conditions without requiring dual in-line sensors. This architecture forms a bridge between clinical IV pump detection and the wearable insulin delivery designs that followed.
Ambulatory Drug InfusionDialysis and Peritoneal Therapy
Vantive Health GmbH (2025, US) and Baxter International (2025, WO) apply dual-threshold negative/positive pressure profile analysis to peritoneal dialysis systems, demonstrating technology transfer between insulin pump and dialysis domains. The methodology detects patient line occlusions and estimates intraperitoneal pressure, sharing algorithmic fundamentals with patch pump pressure-delta approaches. These 2025 filings represent a cross-domain signal for partial-occlusion detection at low delivery rates.
Dialysis SystemsLeading Patent Assignees in Occlusion Detection — Dataset Snapshot
In this dataset, Nestec S.A. and ZEVEX / Moog Inc. hold the highest filing counts with approximately 11 and 10 retrieved records respectively, concentrated in enteral and cassette-based infusion systems. Insulet Corporation and Tandem Diabetes Care hold approximately 7 and 5 records respectively in retrieved records, representing the most active insulin-specific portfolio holders in the patch and tubed pump segment.
Top Assignees by Filing Count — Occlusion Detection (Dataset Snapshot, Retrieved Records)
↗ Click bars to exploreInsulet Corporation
Insulet holds approximately 7 retrieved records in this dataset spanning 2013–2024 across US, EP, and WO jurisdictions, covering optical membrane-deflection systems for OmniPod-type patch pumps and advanced pressure-profile analysis. Key patents include the 2013 US optical membrane system using primary and reference light emitters, the 2023 US/EP pivot-fitting contact timing method for inlet occlusion detection, and the 2024 US/EP pressure-profile classification system that determines occlusion type (partial vs. complete, upstream vs. downstream). These filings are active and represent significant freedom-to-operate considerations for new entrants.
United StatesTandem Diabetes Care, Inc.
Tandem Diabetes Care holds approximately 5 retrieved records in this dataset spanning 2014–2018 across US and WO jurisdictions, all focused on pressure-differential occlusion detection specifically tuned to basal and bolus insulin delivery cycles in the t:slim X2 platform. The foundational 2014 US patent measures pressure differentials before and after each motor move during basal delivery and at common delivery-cycle points during bolus delivery to minimize systematic sensor drift. Continuation filings through 2018 extend the core claims, and these active patents represent a primary IP consideration for any new entrant in tubed insulin pump pressure-differential detection.
United StatesNext-Generation Occlusion Detection Signals (2023–2026)
Among the most recent filings in this dataset (2023–2026), four directional signals point toward a field transitioning from discrete hardware sensors toward integrated, algorithmically rich, and connectivity-enabled occlusion detection.
Pressure-Profile ML and Multi-Type Occlusion Classification
Insulet Corporation’s 2024 US and EP filings explicitly generate both normal-operation and occlusion-specific pressure profiles for comparative classification, enabling detection of occlusion type — partial vs. complete, upstream vs. downstream — rather than simple binary alarm triggering. The system uses a flexible soft-tubing region inside a rigid container coupled to an incompressible fluid and a flexible membrane sensor to accumulate pressure readings over time into a classifiable profile. This approach is particularly suited to the low-flow, low-pressure environment of wearable patch pumps where pressure excursions are subtle.
Sensor-Free Virtual Detection via Motor Current and Stroke Timing
Becton Dickinson’s 2026 US filing and 2021 system patent explicitly frame motor current sensing and pump stroke duration as cost-reducing, complexity-reducing alternatives to added pressure sensors. This approach is a strategic signal for disposable patch pump OEMs designing sub-$10 pods, where sensor hardware must be minimized to reduce BOM cost and regulatory complexity. The 2023 Insulet pivot-fitting contact timing method also derives an occlusion evaluation value from a linear-reciprocating shaft driving time without a dedicated fluid-path transducer.
Direct Pressure Transduction vs. Motor Current–Based Indirect Detection
Click any row to explore further.
| Dimension | Direct Pressure Transduction (Strain Gauge / Piezoresistive) | Motor Current / Drive-Train Indirect Detection |
|---|---|---|
| Dedicated strain-gauge or piezoresistive element monitors fluid pressure directly in the delivery path | Motor current draw, stroke duration, or pivot-contact timing monitored as proxy for downstream backpressure | |
| Hospira/ICU Medical (1999), Tandem Diabetes Care (2014–2018), Pacesetter/MiniMed (1989), Insulet (2013–2024) | MiniMed (2002, WO), Becton Dickinson (2021 US, 2026 US/EP), Insulet (2023, US/EP) | |
| Yes — dedicated fluid-path transducer required; upstream/downstream sensor pairs common | No dedicated fluid-path sensor — uses existing motor control electronics as sensing element | |
| Upstream vs. downstream occlusion distinguishable via dual-sensor differential comparison | Primarily detects increased backpressure as aggregate signal; directionality requires additional logic | |
| Well-established for tubed and patch pumps; miniaturization required for sub-cm² wearable form factors | Explicitly positioned by Becton Dickinson (2021–2026) as cost-reducing for disposable patch pump pods | |
| Insulet 2024 US/EP pressure-profile classification; Roche Diabetes Care 2009; DEKA 2016 | Becton Dickinson 2026 US motor current patent; Insulet 2023 pivot-contact timing; BD 2026 EP occlusion sensor | |
| Significant FTO encumbrance from Tandem (2014–2018) and Insulet (2013–2024) active US/EP portfolios | Smaller active portfolio in this dataset; Becton Dickinson continuation watch recommended | |
| Pressure-profile ML classification (Insulet 2024) enables partial vs. complete and upstream vs. downstream typing | Threshold-based stroke/current comparison; multi-level output declared by MiniMed (2002 WO) |
Frequently Asked Questions: Insulin Pump Occlusion Detection Pressure Sensors
Within this dataset, the four principal sensing modalities are: (1) direct fluid pressure transduction using strain-gauge or piezoresistive elements, (2) membrane-and-optical systems that transduce pressure-driven mechanical deflection into light intensity changes, (3) motor/drive-train parameter monitoring as an indirect proxy for backpressure, and (4) infrared reflective tube-wall deformation sensors.
The earliest patent in this dataset is the 1989 US filing by Pacesetter Infusion / MiniMed Technologies, titled ‘Patient-side occlusion detection system for a medication infusion system.’ It established the core architecture: a piezoresistive downstream pressure transducer coupled to control logic, alarm circuitry, and baseline pressure averaging.
Insulet’s 2024 US and EP filings generate both normal-operation and occlusion-specific pressure profiles over time for comparative classification, enabling detection of occlusion type — partial vs. complete, upstream vs. downstream — rather than simple binary alarm triggering. Earlier approaches relied on fixed absolute pressure thresholds or single differential measurements per pump cycle.
Becton Dickinson’s 2021 and 2026 US filings explicitly frame motor current sensing and pump stroke duration as cost-reducing alternatives to dedicated pressure sensors. For patch pump OEMs designing disposable pods where sensor hardware must be minimized to reduce BOM cost and regulatory complexity, this sensor-free approach is a significant directional signal. IP strategists are advised to monitor BD’s continuation filings for scope creep into insulin-specific delivery modes.
Within this dataset, CN, KR, and JP filings are absent for core insulin pump pressure-sensor occlusion technology. The dataset notes this may reflect either limited search coverage or an opportunity for Asia-focused patent prosecution, given rapid growth of wearable diabetes device manufacturing in China and South Korea. IL (Israel) appears via Biosense Webster for a non-insulin use case, and emerging IN (India) filings appear for both ZEVEX (2016) and the wearable patch pump application (2025).
The 2025 filing by Noida Institute of Engineering and Technology (India) claims a fully integrated wearable insulin patch pump combining MEMS pressure and flow sensors with BLE connectivity, haptic alerts, and NFC-based activation. It is described in this dataset as the most complete integration of sensing, alerting, and connectivity in the retrieved records and a leading indicator of where next-generation patch pump design is heading.
Data and insights on this page are based on a limited patent and literature dataset and are for reference only. Figures may not represent the complete technology landscape.